R7	Anaphora Anaphor:T80 Antecedent:T36
T2	Drug 728 736	NATRECOR
T3	Drug_Class 742 786	drugs affecting the renin-angiotensin system
T4	Drug_Class 794 823	angiotensin receptor blockers
T5	Drug_Class 831 871	angiotensin-converting enzyme inhibitors
T6	Drug_Class 882 900	afterload reducers
T8	Drug_Class 3853 3871	afterload reducers
T9	Drug_Class 3875 3913	affecting the renin-angiotensin system
T10	Drug_Class 3921 3925	ARBs
T11	Drug_Class 3933 3947	ACE inhibitors
T12	Drug 3602 3610	NATRECOR
T13	Drug_Class 4022 4036	ACE inhibitors
T14	Drug_Class 3451 3465	pressor amines
T15	Drug_Class 1753 1772	vasodilating agents
T16	Drug_Class 3434 3449	corticosteroids
T17	Drug 1140 1153	nitroglycerin
T18	Drug 1301 1314	nitroglycerin
T19	Drug 3673 3686	nitroglycerin
T20	Drug 3386 3397	epinephrine
T21	Drug 0 8	NATRECOR
T22	Drug 90 98	NATRECOR
T23	Drug 447 455	NATRECOR
T24	Drug 556 564	NATRECOR
T25	Drug 1119 1127	NATRECOR
T26	Drug 1252 1260	NATRECOR
T27	Drug 1358 1366	NATRECOR
T28	Drug 1502 1510	NATRECOR
T29	Drug 1611 1619	NATRECOR
T30	Drug 1703 1711	NATRECOR
T31	Drug 2144 2152	NATRECOR
T32	Drug 2501 2509	NATRECOR
T33	Drug 2548 2556	NATRECOR
T34	Drug 2919 2927	NATRECOR
T35	Drug 3080 3088	NATRECOR
T36	Drug 3271 3279	NATRECOR
T37	Drug 3976 3984	NATRECOR
T38	Drug 3990 4003	nitroprusside
T39	Drug_Class 3418 3432	antihistamines
T91	SPAN 296 318	Known hypersensitivity
T45	ZeroArticleNP 33 39	powder
T46	ZeroArticleNP 58 66	solution
T47	IndefiniteNP 212 229	an increased risk
T48	ZeroArticleNP 193 200	therapy
T49	PossessivePronoun 329 343	its components
T50	DefiniteNP 482 501	the ASCEND-HF trial
T51	DefiniteNP 503 516	the incidence
T52	IndefiniteNP 630 642	a background
T53	DefiniteNP 661 669	The risk
T54	DefiniteNP 705 724	the concomitant use
T55	IndefiniteNP 876 900	other afterload reducers
T56	ZeroArticleNP 794 823	angiotensin receptor blockers
T57	ZeroArticleNP 831 871	angiotensin-converting enzyme inhibitors
T58	DefiniteNP 905 919	the VMAC trial
T59	DefiniteNP 939 959	the recommended dose
T60	DefiniteNP 1019 1038	the adjustable dose
T61	DefiniteNP 1040 1053	the incidence
T62	DefiniteNP 1084 1102	the first 24 hours
T63	IndefiniteNP 988 1014	a 0.01 mcg/kg/min infusion
T64	DefiniteNP 1196 1208	the duration
T65	DefiniteNP 1475 1483	the dose
T66	IndefiniteNP 1943 1959	other conditions
T67	ZeroArticleNP 1753 1772	vasodilating agents
T68	ZeroArticleNP 2272 2279	therapy
T69	DefiniteNP 2428 2440	the activity
T70	DefiniteNP 2444 2484	the renin-angiotensin aldosterone system
T71	DefiniteNP 2751 2759	the rate
T72	IndefiniteNP 2647 2664	an increased rate
T73	ZeroArticleNP 2722 2740	standard therapies
T74	IndefiniteNP 3010 3019	a history
T75	DemonstrativeNP 2949 2964	These reactions
T76	DefiniteNP 3156 3167	the patient
T77	IndefiniteNP 3176 3212	a previous hypersensitivity reaction
T78	IndefiniteNP 3216 3242	other recombinant peptides
T79	ZeroArticleNP 3067 3074	therapy
T80	DefiniteNP 3300 3308	the drug
T81	IndefiniteNP 3247 3267	an allergic reaction
T82	IndefiniteNP 3310 3358	Some serious hypersensitivity/allergic reactions
T83	ZeroArticleNP 3451 3465	pressor amines
T84	ZeroArticleNP 3515 3521	7 DRUG
T85	ZeroArticleNP 3569 3596	potential drug interactions
T86	ZeroArticleNP 3636 3658	many concomitant drugs
T87	IndefiniteNP 3792 3803	an increase
T88	ZeroArticleNP 3933 3947	ACE inhibitors
T89	DefiniteNP 3951 3972	The co-administration
T90	ZeroArticleNP 4019 4036	IV ACE inhibitors
